MGCD-265 – 10 mg

Brand:
Cayman
CAS:
875337-44-3
Storage:
-20
UN-No:
Non-Hazardous - /

MGCD-265 is an orally bioavailable, multi-targeted tyrosine kinase inhibitor, inhibiting MET, VGFR1-3, Tie, and Ron. Formulations containing MGCD-265, alone or in combination with other chemotherapeutic compounds, are being tested in animal models and clinical cancer trials, particularly for non-small cell lung cancer.{29344}  

 

Available on backorder

SKU: 20097 - Category:

Description

An orally bioavailable, multi-targeted tyrosine kinase inhibitor, inhibiting MET, VGFR1-3, Tie, and Ron


Formal name: N-[[[3-fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]-benzeneacetamide

Synonyms:  Glesatinib

Molecular weight: 517.6

CAS: 875337-44-3

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|Other Receptor Tyrosine Kinases||Product Type|Biochemicals|Kinase Inhibitors|VEGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling